In today’s recent session, 0.68 million shares of the Adma Biologics Inc (NASDAQ:ADMA) have been traded, and its beta is 0.67. Most recently the company’s share price was $19.21, and it changed around $0.17 or 0.90% from the last close, which brings the market valuation of the company to $4.28B. ADMA at last check was trading at a discount to its 52-week high of $23.64, offering almost -23.06% off that amount. The share price’s 52-week low was $3.60, which indicates that the recent value has risen by an impressive 81.26% since then. We note from Adma Biologics Inc’s average daily trading volume that its 10-day average is 4.35 million shares, with the 3-month average coming to 5.16 million.

Adma Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended ADMA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Adma Biologics Inc is expected to report earnings per share of 0.16 for the current quarter.

Adma Biologics Inc (NASDAQ:ADMA) trade information

Instantly ADMA has been showing a green trend so far today with a performance of 0.90% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 22.55 on recent trading dayincreased the stock’s daily price by 14.81%. The company’s shares are currently up 325.02% year-to-date, but still down -14.54% over the last five days. On the other hand, Adma Biologics Inc (NASDAQ:ADMA) is 21.74% up in the 30-day period. We can see from the shorts that 15.2 million shares have been sold at a short interest cover period of 3.53 day(s).

The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to decrease their stock price by -20.06% from its current value. Analyst projections state that ADMA is forecast to be at a low of $14 and a high of $18.

Adma Biologics Inc (ADMA) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 307.89% in revenue this quarter, and will report an increase of 96.88% in the next quarter. The year-over-year growth rate is expected to be 63.57%, up from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 113.4M in revenue for the current quarter. 4 analysts expect Adma Biologics Inc to make 112.9M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 73.9M and 81.88M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 53.44%. Forecasts for the next quarter put sales growth at 37.89%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 38.68%. Adma Biologics Inc earnings are expected to increase by 494.23% in 2024, but the outlook is positive 20.00% per year for the next five years.

ADMA Dividends

Adma Biologics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.

Adma Biologics Inc (NASDAQ:ADMA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 2.55% of Adma Biologics Inc shares, and 90.74% of them are in the hands of institutional investors. The stock currently has a share float of 93.11%. Adma Biologics Inc stock is held by 405.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 8.1462% of the shares, which is about 18.64 million shares worth $208.45 million.

VANGUARD GROUP INC, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.